{
    "2019-11-13": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes",
                "features": {
                    "keywords": [
                        "FDA Advisory Committee",
                        "empagliflozin",
                        "Lilly",
                        "Boehringer Ingelheim",
                        "type 1 diabetes"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "n/a"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug",
                "features": {
                    "keywords": [
                        "FDA panel",
                        "voted against",
                        "diabetes drug",
                        "Lilly-Boehringer Ingelheim"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "n/a"
                }
            }
        ]
    ]
}